Belrestotug is a monoclonal antibody commercialized by iTeos Therapeutics, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 1 was completed, and 6 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Belrestotug’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Belrestotug is expected to reach an annual total of $8 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
EOS-448 is under development for the treatment of solid tumors, non-small cell lung cancer, squamous non-small cell lung cancer, PD-1 resistant melanoma and head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The drug candidate is a checkpoint blocking antibody acts by targeting TIGIT.
It was also under development for the treatment of relapsed or refractory multiple myeloma.
iTeos Therapeutics Overview
iTeos Therapeutics is a clinical-stage biopharmaceutical company. It discovers and develops immuno-oncology drugs for cancer. The company’s pipeline products are EOS-448, EOS-984, dostarlimab, iberdomide, pembrolizumab, CD96 drug candidates. Its products are used to treat various cancers like advanced malignancies, relapsed refractory multiple myeloma. The drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations. Its service includes to carries out clinical trials for inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy. It has operational presence in the US; and Belgium. iTeos Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$267.6 million for the fiscal year ended December 2022 (FY2022), a decrease of 22.4% over FY2021. In FY2022, the company’s operating margin was 47.2%, compared to an operating margin of 71% in FY2021. In FY2022, the company recorded a net margin of 36.1%, compared to a net margin of 62.2% in FY2021.
For a complete picture of Belrestotug’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.